|
DUBLIN, Ireland (AP) - Ireland's Elan Corp. PLC and Wyeth of the United States said Monday they are planning advanced trials of a drug to combat Alzheimer's, the incurable brain disease that afflicts more than 20 million people worldwide.
The pharmaceutical companies are seeking regulatory approval to begin advanced "phase 3" trials of bapineuzumab, which they hope will eventually be used to stop the memory loss and dementia symptomatic of Alzheimer's.
Both companies said they plan to begin advanced studies in the second half of 2007 — several months ahead of their previous target — but do not expect to announce results from their current mid-stage, "phase 2" trials until 2008.
|